| Patent Number |
Title Of Patent |
Date Issued |
| 7449561 |
Alterations in the dystrophin gene associated with sporadic dilated cardiomyopathy |
November 11, 2008 |
| The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to detect a human sporadic DCM predisposing gene, specifically the dystrophin gene, some mutant alleles of which cause susceptibility to s |
| 7446191 |
DNA construct encoding CE7-specific chimeric T cell receptor |
November 4, 2008 |
| Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular |
| 7446179 |
CD19-specific chimeric T cell receptor |
November 4, 2008 |
| The present invention relates to a genetically engineered, CD19-specific chimeric T cell receptor and to immune cells expressing the chimeric receptor The present invention also relates to the use of such cells for cellular immunotherapy of CD9.sup.+ malignancies and for abrogating any |
| 7425415 |
Method for detecting methylated CpG islands |
September 16, 2008 |
| The present invention provides new and improved assay for detection of genomic methylated CpG islands. This new method is termed the methylated-CpG island recovery assay (MIRA). In accordance with one embodiment, MIRA comprises the steps of: (a) incubating genomic DNA fragments with |
| 7402436 |
Lentiviral vectors for site-specific gene insertion |
July 22, 2008 |
| Murine leukemia virus (MLV) and lentivirus vectors have been used previously to deliver genes to hematopoietic stem cells (HSCs) in human gene therapy trials. However, these vectors integrate randomly into the host genome, leading to disruption or inactivation of vital host genes. Th |
| 7390298 |
Expandable surgical retractor for internal body spaces approached with minimally invasive incisi |
June 24, 2008 |
| An expandable surgical retractor for use in minimal incision surgery is disclosed. The retractor consists of a fiber optic central rod surrounded by flexible wires designed to create an open space for visualization and surgical work within an illuminated surgical field. The flexible wire |
| 7387782 |
Protein kinase deficient, immunologically active CMVpp65 mutants |
June 17, 2008 |
| This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and |
| 7354762 |
Method for producing CE7-specific redirected immune cells |
April 8, 2008 |
| Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular |
| 7329745 |
Single-chain antibodies against human insulin-like growth factor I receptor: expression, purific |
February 12, 2008 |
| A method of inhibiting the growth of hormone dependent tumor cells in a mammal comprises administering to said mammal an insulin-like growth factor receptor (IGF-IR) recombinant antibody, wherein said antibody can be a single-chain recombinant antibody, which can be humanized, capable |
| 7320988 |
Methods of lowering lipid levels in a mammal |
January 22, 2008 |
| This invention relates to methods for lowering lipid levels in mammals using compounds that inhibit advanced glycation endproducts (AGEs), LR-9, LR-74 and LR-90. These compounds, which inhibit non-enzymatic protein glycation, also inhibit the formation of advanced lipoxidation endpro |
| 7273608 |
Humanized anti-CEA T84.66 antibody and uses thereof |
September 25, 2007 |
| Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum s |
| 7265209 |
CE7-specific chimeric T cell receptor |
September 4, 2007 |
| Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular |
| 7256037 |
Modified vaccinia Ankara expressing p53 in cancer immunotherapy |
August 14, 2007 |
| Mutations to the tumor suppressor protein p53 have been observed in 40-60% of all human cancers. These mutations are often associated with high nuclear and cytoplasmic concentrations of p53. Since many tumors exhibit highly elevated p53 levels, the protein is an attractive target for |
| 7238480 |
Pyrophosphorolysis activated polymerization (PAP) |
July 3, 2007 |
| A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3'-deoxynucleotide |
| 7223548 |
Method of screening a chemical for binding to a proline-rich nuclear receptor co-regulatory prot |
May 29, 2007 |
| The invention relates to assays for screening for chemicals which affect the binding between proteins comprising an SH3 binding motif (such as Proline-rich Nuclear Receptor Co-regulatory protein (PNRC)) and nuclear receptor proteins. Compounds which affect the binding of PNRC to nuclear |
| 7163685 |
Human cytomegalovirus antigens expressed in MVA and methods of use |
January 16, 2007 |
| DNA and protein constructs useful in producing vaccines against human cytomegalovirus contain optionally N-end modified and N-terminal ubiquitinated human cytomegalovirus antigenic proteins, including pp65, pp150, IE1, gB and antigenic fragments thereof. Vaccine viruses, in particula |
| 7160685 |
Diagnostic reagents for human cytomegalovirus and methods of use |
January 9, 2007 |
| The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8.sup.+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) infection. The peptides are |
| 7141153 |
pK-matched running buffers for gel electrophoresis |
November 28, 2006 |
| pK-matched buffers, each containing two effective buffering components: one weak base and one weak acid which have similar pK.sub.a at 25.degree. C. (within 0.3 pK units). On agarose gels, the buffers in various concentrations were tested for separation of double-stranded DNA fragmen |
| 7122348 |
AAV2 Rep protein fusions |
October 17, 2006 |
| This invention pertains to methods for promoting stable and site-specific integration of rep deleted recombinant adeno-associated virus vectors which result in less variable transgene expression and increased safety. These vectors are useful for delivery of a functional gene product to t |
| 7105298 |
Serial coupling of restriction cleavage and extension for nucleic acid amplification |
September 12, 2006 |
| A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendable 3'-deoxynucleotide |
| 7083926 |
Method for identifying accessible binding sites on RNA |
August 1, 2006 |
| A method for identifying sites on a target RNA which are accessible to pairing by antisense DNA, ribozymes or DNAzymes. Native or in vitro-synthesized target RNA is incubated with defined ODNs and RNase H, or with a random or semi-random ODN library and RNase H, or with defined riboz |
| 7070995 |
CE7-specific redirected immune cells |
July 4, 2006 |
| Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such cells for cellular |
| 7047990 |
Articulated cane |
May 23, 2006 |
| An improved cane to assist walking, comprising a shaft, a base and an articulated connection allowing the base to pivot relative to the shaft, depending upon the slope of the surface below the base, the connection characterized in that articulation capability decreases as downward lo |
| 7033763 |
Pyrophosphorolysis activated polymerization (PAP) |
April 25, 2006 |
| A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3'-deoxynucleotide |
| 7030133 |
Inhibitors of formation of advanced glycation endproducts (AGEs) |
April 18, 2006 |
| The nonenzymatic glycation and crosslinking of proteins is a part of the aging process with the glycation endproducts and crosslinking of long-lived proteins increasing with age. This process is increased at elevated concentrations of reducing sugars in the blood and in the intracell |
| 7025969 |
Protein kinase deficient, immunologically active CMVpp65 mutants |
April 11, 2006 |
| This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and |
| 6995258 |
Nucleolar targeting of therapeutics against HIV |
February 7, 2006 |
| The HIV regulatory proteins Tat and Rev accumulate in nucleoli of human cells. No functional role has been attributed to this localization. Recently it was demonstrated that expression of Rev induces nucleolar re-localization of some nuclear factors involved in Rev export. Thus, it i |
| 6972178 |
Drug screening using a proline-rich nuclear receptor co-regulatory protein/nuclear receptor co-e |
December 6, 2005 |
| Assays are presented for screening for chemicals which affect the binding between proteins comprising an SH3 binding motif and nuclear receptor proteins. PNRC (Proline-rich Nuclear Receptor Co-regulatory protein) is a co-regulatory protein comprising an SH3 binding motif and was identifi |
| 6951651 |
CTL epitope analogs |
October 4, 2005 |
| We have screened the HCMV-specific T cell clone, 33F4, with a nonamer PS-SCL based on SEQ ID NO: 1, and described a series of analog peptides that are recognized with greater affinity than the native peptide sequence. |
| 6950755 |
Genotype pattern recognition and classification |
September 27, 2005 |
| Interpreting data obtained by analysis of nucleic acids (DNA) by obtaining nucleic acid data in a spatial domain, transforming the nucleic acid data from the spatial domain into a frequency domain, and obtaining sequence data of the nucleic acid data by executing a data mining process on |
| 6926724 |
Visceral anastomotic device and method of using same |
August 9, 2005 |
| A temporary biocompatible stent and method for visceral anastomosis. The stent is provided with integral means for maintaining the structural stability of the stent while providing substantial flexibility. The method comprises fitting the luminal stumps of the viscus over either end of a |
| 6919209 |
Method of genetically modifying very primitive quiescent human hematopoietic stem cells |
July 19, 2005 |
| This invention relates to a method for transducing extremely primitive hematopoietic stem cells with high efficiency, using an adeno-associated vector. This vector stably transforms highly primitive CD34.sup.+++ CD38.sup.= cells which reside in a quiescent state and retain to a larger |
| 6893829 |
Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states |
May 17, 2005 |
| The present invention relates to a method for inhibiting the etiology of disease in patients having a disease state caused by an excess of 12-lipoxygenase or its products. In particular, the invention provides for administration of a human leukocyte 12-lipoxygenase pathway inhibitor to |
| 6869768 |
Association between the acid phosphatase (ACP1) gene and Alzheimer's disease |
March 22, 2005 |
| Alzheimer's disease is characterized by the presence of senile plaques formed from beta amyloid (A.beta.), and neurofibrillary tangles (NTFs) formed from paired helical filaments consisting of hyperphosphorylated tau. A number of studies have shown that the NTFs correlate better with |
| 6843992 |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
January 18, 2005 |
| The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8.sup.+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) infection. The peptides are |
| 6835383 |
Protein kinase deficient, immunologically active CMVpp65 mutants |
December 28, 2004 |
| This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and |
| 6787566 |
Breakers of advanced glycation endproducts |
September 7, 2004 |
| Advanced glycation endproducts (AGEs) have been implicated in the pathogenesis of a variety of debilitating diseases such as diabetes, atherosclerosis, Alzheimer's and rheumatoid arthritis, as well as in the normal aging process. Seven compounds are here reported to be active in brea |
| 6770749 |
P53-specific T cell receptor for adoptive immunotherapy |
August 3, 2004 |
| The present invention relates to molecular cloning of cDNA for both A and B chains of hu p53-specific, HLA restricted mu TCR, transfer of the cDNA to hu T cells, and functional expression of the p53-specific TCR in hu CTLs. The functional expression of the mu TCR results in the recogniti |
| 6762343 |
Mice with combined disruption of Gpx1 and Gpx2 genes have growth retardation, hypothermia, and c |
July 13, 2004 |
| Disclosed is a transgenic knockout mouse whose genome has a homozygous disruption in its endogenous Gpx1 and Gpx2 genes, wherein the disruptions result in a decrease in GPX activity in the transgenic mice when compared to non transgenic mice of the same type. Methods for production of th |
| 6743589 |
Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women |
June 1, 2004 |
| The present invention relates to the observation that women having an A.fwdarw.T 1890 polymorphism in the 3' UTR of the cholinergic muscarinic receptor 2 (CHRM2) gene have an increased risk for developing major depression. The present invention provides diagnostic, screening and ther |
| 6734024 |
Ferrocenyl boronate derivatization of chemical compounds undergoing mass spectrometry analysis |
May 11, 2004 |
| An improved mass spectrometry method comprises the analysis of ferrocenyl boronate derivatives of compounds of interest. Chemical derivatization with ferrocenyl boronate overcomes problems resolving small structural differences in a variety of biologically important compounds, including |
| 6733973 |
Diagnostic reagents for human cytomegalovirus and methods of use |
May 11, 2004 |
| The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8.sup.+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) infection. The peptides are |
| 6727093 |
HCMV-reactive T cells and uses therefor |
April 27, 2004 |
| The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8.sup.+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) infection. The peptides are |
| 6726910 |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
April 27, 2004 |
| The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8.sup.+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) infection. The peptides are |
| 6716972 |
Method for breeding and genotyping chickens and probes therefor |
April 6, 2004 |
| Disease resistance in domesticated fowl, and in particular, chickens, has been associated with certain alleles of the Rfp-Y and B systems of major histocompatibility genes in the birds. This invention provides a method of genotyping chickens which is useful for different breeds of chicke |
| 6696253 |
Method for determining the MHC genotype of chickens |
February 24, 2004 |
| Disease resistance in domesticated fowl has been associated with the B and Rfp-Y systems of major histocompatability genes. A method for breeding domesticated fowl to produce disease resistant offspring involves selecting at least one parent that has a B genotype, an Rfp-Y genotype or |
| 6693106 |
Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation end |
February 17, 2004 |
| Pentoxifylline, pioglitazone and metformin have been found to inhibit the nonenzymatic glycation of proteins which often results in formation of advanced glycation endproducts and crosslinks. The nonenzymatic glycation and crosslinking of proteins is a part of the aging process with the |
| 6667164 |
Method for determining the MHC genotype of chickens |
December 23, 2003 |
| Disease resistance in domesticated fowl has been associated with the B and Rfp-Y systems of major histocompatability genes. A method for breeding domesticated fowl to produce disease resistant offspring involves selecting at least one parent that has a B genotype, an Rfp-Y genotype or |
| 6660476 |
Polymorphisms in the PNMT gene |
December 9, 2003 |
| The present invention is directed to two single nucleotide polymorphisms, identified as G-182A and G-387A, in the promoter region of the human phenylethanolamine N-methyltransferase (PNMT) gene, the gene products thereof, and to methods for the determination (diagnosis) of susceptibi |
| 6653073 |
Association of the serotonin transport (HTT) gene with cardiovascular disease and longevity |
November 25, 2003 |
| Disclosed are methods for screening subjects to determine their risk for developing cardiovascular disease, screening methods to determine potential longevity, therapeutic methods and compositions for treating patients at risk for developing cardiovascular disease, and screening meth |
